Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03049618 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC(VERSATILE002) | completed | Phase 2 | 95 | PDS Biotechnology Corp.INDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05271604 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 42 | BioAtla, Inc.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05459129 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | completed | Phase 1 / Phase 2 | 12 | Hoffmann-La RocheINDUSTRY | 3 | Sep 15, 2025 | clinicaltrials |
| NCT05323656 | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | completed | Phase 2 | 55 | Calliditas Therapeutics Suisse SAINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT03623646 | Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.(CITHARE) | completed | Phase 2 | 11 | Institut Claudius RegaudOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05156970 | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | completed | Phase 2 | 81 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03795610 | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Assuntina G. Sacco, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | completed | Phase 1 / Phase 2 | 25 | Nektar TherapeuticsINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT03317327 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors(REPORT) | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05499065 | Real-time Margin Assessment in Head and Neck Cancer(LIGHTNING) | completed | Phase 2 | 23 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT05516589 | Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC(neoCHANCE-2) | completed | Phase 2 | 40 | West China HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT04555837 | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03944915 | De-Escalation Therapy for Human Papillomavirus Negative Disease(DEPEND) | completed | Phase 2 | 35 | University of ChicagoOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03212469 | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer(ABIMMUNE) | completed | Phase 1 / Phase 2 | 54 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT04278092 | Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | completed | Phase 2 | 57 | Medical University of ViennaOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT03107182 | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer(OPTIMA-II) | completed | Phase 2 | 72 | University of ChicagoOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | completed | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04752384 | Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients | completed | Phase 2 | 20 | Medical College of WisconsinOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT03602911 | A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients | completed | Phase 2 | 20 | West Virginia UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03715946 | Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | completed | Phase 2 | 40 | Robert L. Ferris, MD, PhDOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma(NEOPBOSCC) | completed | Phase 2 | 68 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04815720 | Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(KEYNOTE-B84) | completed | Phase 1 / Phase 2 | 49 | Vaccinex Inc.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT02573493 | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)(APA) | completed | Phase 2 | 96 | Washington University School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03946358 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)(VolATIL) | completed | Phase 2 | 47 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03878979 | Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT04144517 | A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer | completed | Phase 2 | 14 | Mural Oncology, IncINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer(OPTIMA) | completed | Phase 2 | 62 | University of ChicagoOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT03521570 | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer | completed | Phase 2 | 62 | Emory UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02777385 | Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | completed | Phase 2 | 80 | Dan ZandbergOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02383927 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | completed | Phase 2 | 63 | Kura Oncology, Inc.INDUSTRY | 10 | Jul 11, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03719690 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy(AIM-HN/SEQ-HN) | completed | Phase 2 | 296 | Kura Oncology, Inc.INDUSTRY | 16 | Jun 21, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04107103 | Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma(NivoPlus) | completed | Phase 2 | 6 | AHS Cancer Control AlbertaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06446570 | Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma | completed | Phase 2 | 18 | Seoul National University HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04939480 | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN(PIONEER) | completed | Phase 2 | 20 | University Hospital, EssenOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03723967 | FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel(FRAIL-IMMUNE) | completed | Phase 2 | 104 | Centre Leon BerardOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03426657 | Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC | completed | Phase 2 | 120 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05918224 | Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy | completed | Phase 2 | 160 | West China HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity(INSPIRE) | completed | Phase 2 | 105 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 4 | Jan 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 22, 2025source: clinicaltrials